Drug intelligence / Profile preview

GNS-20I11

Development stage: Preclinical
Lead developer: Genewon Science
Modality: Small Molecules

Overview

GNS-20I11 is an **improved-drug small-molecule program** developed by GenuOne for diabetes. GenuOne lists the asset in its endocrine pipeline as a diabetes therapeutic, but has not publicly disclosed its active ingredient, molecular target, mechanism of action, formulation, route of administration, or clinical development phase.

Beyond the preview

Go deeper on GNS-20I11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNS-20I11.

Explore the full profile